First At Home Test For Vasectomized Men Proves To Be Safe, Accurate

Main Category: Fertility
Also Included In: Men's health;  Urology / Nephrology;  Clinical Trials / Drug Trials
Article Date: 14 Nov 2008 - 0:00 PST

email to a friend   printer friendly   view / write opinions   rate article

In a report now available online and scheduled to be the cover story of the December 2008 issue of the Journal of Urology, University of Virginia Health System researcher John C. Herr, PhD and his colleagues have confirmed the accuracy and reliability of SpermCheck Vasectomy, the first FDA approved at-home immunodiagnostic test for detecting low concentrations of sperm.

Herr, a professor of Cell Biology and director of UVA's Center for Research in Contraceptive and Reproductive Health, discovered and patented the biomarker on which SpermCheck is based. The newly reported research consisted of a clinical trial and consumer study.

In the clinical trial, researchers used SpermCheck to evaluate a cohort of 144 post-vasectomy semen samples. The test achieved an accuracy rate of 96 percent in identifying whether sperm counts were greater or less than a threshold of 250,000 sperm per ml a level associated with little or no risk of causing pregnancy. SpermCheck proved to be 100 percent accurate in identifying whether sperm counts were greater or less than 384,000 sperm per ml.

According to the World Health Organization Manual on Semen Analysis, normal sperm counts range from 20,000,000/ml to as high as 200,000,000/ml. When the count is below 1,000,000/ml, there is only a remote chance of achieving pregnancy without assisted reproductive techniques such as intra-uterine insemination, in-vitro fertilization and intra-cytoplasmic sperm injection.

In the consumer study of SpermCheck, 109 lay volunteers demonstrated its ease of use. Volunteers obtained the correct or expected test result in every case and achieved a 97 percent correct response rate on a 20-question survey about the test.

Herr, who is now involved in commercializing SpermCheck through a start-up company, believes the product will make it easier for men to comply with post-vasectomy monitoring. Traditionally, the process has involved bringing semen samples to a physician's office or laboratory at two- and three-month intervals after the procedure. Monitoring is important because vasectomies are not 100 percent successful, and men who have had them can experience recanalization, or the spontaneous healing or restoration of the vas deferens, which restores their fertility.

"SpermCheck Vasectomy is similar in size and function to a women's home pregnancy test," Herr says. "It's designed to help couples monitor and confirm that post-vasectomy sperm concentrations have reached infertile levels and avoid any surprises if recanalization occurs."

According to the National Institutes of Child Health and Human Development, some 500,000 men undergo vasectomies in the U.S. each year, making vasectomy the third most popular contraceptive option among the nation's married couples. The National Institutes of Health reports that one in six men over age 35 have had a vasectomy.

Related links:

http://www.jurology.com/article/PIIS0022534708021733/abstract?rss=yes "Clinical and Consumer Trial Performance of a Sensitive Immunodiagnostic Home Test That Qualitatively Detects Low Concentrations of Sperm Following Vasectomy," The Journal of Urology, Volume 180, Issue 6, Pages 2569-2576 (December 2008).

University of Virginia Health System
PO Box 800795
Charlottesville
VA 22908-0795
United States
http://www.healthsystem.virginia.edu